Hypermethylation of Promoter Plays Oncogenic Roles in Development of Clear Cell Renal Cell Carcinoma

Overview

Journal J Cancer

Specialty Oncology

Date 2019 Oct 12

PMID 31602276

Citations 1

Authors

Ru Fang

Qiuyuan Xia

Jing Sun

Hao Zha Ng

Yan Liang

Xiaotong Wang

Xuan Wang

Henghui Ma

Xiaojun Zhou

Yang Cheng

Qiu Rao

Affiliations

Soon will be listed here.

Abstract

Although the inactivation of plays oncogenic roles in tumorigenesis, regulation mechanism is rarely studied in clear cell renal cell carcinoma (RCC). Thus, we aimed to investigate the mechanism of inactivation and explore the tumor suppressing roles of in the development of clear cell RCC. We verified that hypermethylation of the promoter was correlated with decreased expression of by multi-omics analysis based on the TCGA database. This result was further confirmed in our own tumor tissues. Moreover, inhibited the ability of proliferation and invasion of RCC cells . Consistent with this, overexpressing virtually inhibited the xenograft tumor growth of ACHN cells . Finally we found that promoted cell apoptosis and cellular cycle arrest in G2/M. In conclusion, our study confirms that the hypermethylation of promoters plays oncogenic roles by the transcription inhibition of in RCC, and the tumor suppressor gene inhibits RCC cell vitality and

Citing Articles

Essential role of bromodomain proteins in renal cell carcinoma (Review).

Wen Q, Liu H, Lou K, Zhang X, Chao W, Xin J Mol Med Rep. 2023; 28(1).

PMID: 37293842 PMC: 10280547. DOI: 10.3892/mmr.2023.13026.

References

Wiegand K, Shah S, Al-Agha O, Zhao Y, Tse K, Zeng T . ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010; 363(16):1532-43. PMC: 2976679. DOI: 10.1056/NEJMoa1008433. View

Ibragimova I, Maradeo M, Dulaimi E, Cairns P . Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC. Epigenetics. 2013; 8(5):486-93. PMC: 3741218. DOI: 10.4161/epi.24552. View

Muchardt C, Yaniv M . ATP-dependent chromatin remodelling: SWI/SNF and Co. are on the job. J Mol Biol. 1999; 293(2):187-98. DOI: 10.1006/jmbi.1999.2999. View

Hassan A, Neely K, Vignali M, Reese J, Workman J . Promoter targeting of chromatin-modifying complexes. Front Biosci. 2001; 6:D1054-64. DOI: 10.2741/hassan. View

Liao L, Testa J, Yang H . The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer. Cancer Genet. 2015; 208(5):206-14. PMC: 4494076. DOI: 10.1016/j.cancergen.2015.02.008. View

Wilson B, Roberts C . SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer. 2011; 11(7):481-92. DOI: 10.1038/nrc3068. View

Gramling S, Rogers C, Liu G, Reisman D . Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy. Oncogene. 2011; 30(29):3289-94. PMC: 3402205. DOI: 10.1038/onc.2011.80. View

Phelan M, Sif S, Narlikar G, Kingston R . Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. Mol Cell. 1999; 3(2):247-53. DOI: 10.1016/s1097-2765(00)80315-9. View

Glaros S, Cirrincione G, Muchardt C, Kleer C, Michael C, Reisman D . The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene. 2007; 26(49):7058-66. DOI: 10.1038/sj.onc.1210514. View

10.

Reisman D, Glaros S, Thompson E . The SWI/SNF complex and cancer. Oncogene. 2009; 28(14):1653-68. DOI: 10.1038/onc.2009.4. View

11.

Monti S, Chapuy B, Takeyama K, Rodig S, Hao Y, Yeda K . Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012; 22(3):359-72. PMC: 3778921. DOI: 10.1016/j.ccr.2012.07.014. View

12.

Shain A, Pollack J . The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One. 2013; 8(1):e55119. PMC: 3552954. DOI: 10.1371/journal.pone.0055119. View

13.

Jones S, Wang T, Shih I, Mao T, Nakayama K, Roden R . Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010; 330(6001):228-31. PMC: 3076894. DOI: 10.1126/science.1196333. View

14.

Yamamichi N, Inada K, Ichinose M, Yamamichi-Nishina M, Mizutani T, Watanabe H . Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state. Cancer Res. 2007; 67(22):10727-35. DOI: 10.1158/0008-5472.CAN-07-2601. View

15.

Pawlowski R, Muhl S, Sulser T, Krek W, Moch H, Schraml P . Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer. 2012; 132(2):E11-7. DOI: 10.1002/ijc.27822. View

16.

Hohmann A, Vakoc C . A rationale to target the SWI/SNF complex for cancer therapy. Trends Genet. 2014; 30(8):356-63. PMC: 4112150. DOI: 10.1016/j.tig.2014.05.001. View

17.

Keefe S, Nathanson K, Rathmell W . The molecular biology of renal cell carcinoma. Semin Oncol. 2013; 40(4):421-8. DOI: 10.1053/j.seminoncol.2013.05.006. View

18.

Xia Q, Rao Q, Cheng L, Shen Q, Shi S, Li L . Loss of BRM expression is a frequently observed event in poorly differentiated clear cell renal cell carcinoma. Histopathology. 2014; 64(6):847-62. DOI: 10.1111/his.12334. View

19.

Masliah-Planchon J, Bieche I, Guinebretiere J, Bourdeaut F, Delattre O . SWI/SNF chromatin remodeling and human malignancies. Annu Rev Pathol. 2014; 10:145-71. DOI: 10.1146/annurev-pathol-012414-040445. View

20.

Shen H, Powers N, Saini N, Comstock C, Sharma A, Weaver K . The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res. 2008; 68(24):10154-62. PMC: 2858924. DOI: 10.1158/0008-5472.CAN-08-1794. View